dengue tetravalent vaccine, live attenuated

A **live attenuated tetravalent dengue vaccine** designed to prevent dengue disease caused by all four dengue virus serotypes (1, 2, 3, 4). Dengue tetravalent vaccines aim to provoke immune responses to all serotypes, minimizing the risk of severe dengue (including antibody-dependent enhancement). Several formulations exist: - **CYD-TDV (Dengvaxia)**, developed by recombinant DNA technology, is a chimeric vaccine using a yellow fever virus backbone expressing the prM and E proteins from each dengue serotype[1][3]. - **TAK-003**, developed by Takeda, is based on a live-attenuated DENV-2 backbone with prM/E genes from the other serotypes[4][5]. - **TV003/TV005**, developed by NIH, contains a mixture of live-attenuated viruses representing each serotype[3]. Mechanism of action: induces a broad, tetravalent immune response—priming neutralizing antibody and cellular immunity to all four dengue virus serotypes, preventing dengue infection and severe disease[1][3][4]. Indications: Prevention of dengue disease in individuals with prior dengue infection (for CYD-TDV/Dengvaxia); indications for other formulations may include naïve individuals (e.g., TAK-003 has demonstrated protection regardless of baseline serostatus in clinical trials).

Brand names

DengvaxiaQdenga

Other names

dengue tetravalent vaccine, livelive attenuated dengue vaccine